Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3444552 | 0.94 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LOPRD1 | |
| Sulfuric Acid SCHEMBL3444555 | 0.94 | KMT2A (0.61) | KMT2AEPHX2CASP3DOT1LOPRD1 | |
| Potassium Ion SCHEMBL385052 | 0.88 | KMT2A (0.60) | KMT2AEPHX2CASP3DOT1LFABP7 | |
| SCHEMBL13417651 | 0.87 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP7FABP5 | |
| Sulfuric Acid SCHEMBL6026967 | 0.85 | KMT2A (0.58) | KMT2AEPHX2CASP3DOT1L | |
| SCHEMBL119596 | 0.84 | KMT2A (0.60) | KMT2AEPHX2CASP3DOT1LFABP7 | |
| SCHEMBL29792075 | 0.84 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL178801 | 0.84 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29370234 | 0.84 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL19450607 | 0.83 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2174946-B1 | Methods for chemically synthesizing immunoglobulin chimeric proteins | BIOGEN HEMOPHILIA INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8133985-B2 | Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same | PANAGENE INC. (KR) | 2012-03-13 | — | — | US | disclosed |
| US-8133985-B2 | Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same | PANAGENE INC. (KR) | 2012-03-13 | — | — | US | disclosed |
| US-20110159540-A1 | Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins | BIOVERATIV THERAPEUTICS INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7820162-B2 | Recombinantly preparing antibody fusion for targeting and/or treating metabolic disorders | SYNTONIX PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7816388-B2 | Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-10-19 | — | — | US | disclosed |
| EP-2174946-A1 | Methods for chemically synthesizing immunoglobulin chimeric proteins | SYNTONIX PHARMACEUTICALS, INC. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2009-12-17 | — | — | US | disclosed |
| EP-1928508-B1 | BIOTIN DIAMINODERIVATIVES AND THEIR CONJUGATES WITH MACROCYCLIC CHELATING AGENTS | SIGMA TAU IND FARMACEUTI (IT) | 2009-11-11 | — | — | EP | disclosed |
| EP-1654378-B1 | METHODS FOR CHEMICALLY SYNTHESIZING IMMUNOGLOBULIN CHIMERIC PROTEINS | SYNTONIX PHARMACEUTICALS INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080249288-A1 | Recombinantly preparing antibody fusion for targeting and/or treating metabolic disorders | SYNTONIX PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249152-A1 | Biotin Diaminoderivatives and Their Conjugates With Macrocyclic Chelating Agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-09 | — | — | US | disclosed |
| WO-2008072933-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI -AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2008-06-19 | — | — | WO | disclosed |
| US-7381408-B2 | Methods for chemically synthesizing immunoglobulin chimeric proteins | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1654378-A4 | METHODS FOR CHEMICALLY SYNTHESIZING IMMUNOGLOBULIN CHIMERIC PROTEINS | SYNTONIX PHARMACEUTICALS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1654378-A2 | METHODS FOR CHEMICALLY SYNTHESIZING IMMUNOGLOBULIN CHIMERIC PROTEINS | SYNTONIX PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050027109-A1 | Preparing genetically engineered therapeutic protein fusion comprised of antibody constant region for use in treatment of metabolic disorders | BIOVERATIV THERAPEUTICS INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004101739-A2 | METHODS FOR CHEMICALLY SYNTHESIZING IMMUNOGLOBULIN CHIMERIC PROTEINS | SYNTONIX PHARMACEUTICALS, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | NPPA, PARN, PARG | KMT2A 548/4885EPHX2 3887/4885CASP3 3534/4885 |
| US-20080249152-A1 | Biotin Diaminoderivatives and Their Conjugates With Macrocyclic Chelating Agents | BTD, HLCS, SLC19A2 | KMT2A 3200/4885EPHX2 2254/4885CASP3 2383/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | KMT2A 4447/4885EPHX2 3220/4885CASP3 3215/4885 |
| US-20080249288-A1 | Recombinantly preparing antibody fusion for targeting and/or treating metabolic disorders | GLS2, FCGR2A, FCGR3B | KMT2A 3367/4885EPHX2 1134/4885CASP3 4825/4885 |
| US-20050027109-A1 | Preparing genetically engineered therapeutic protein fusion comprised of antibody constant region for use in treatment of metabolic disorders | FCGRT, FCGR2A, FCGR3B | KMT2A 2956/4885EPHX2 2072/4885CASP3 4878/4885 |
| US-20110159540-A1 | Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins | FCGR1A, FCGR2A, FCGR3B | KMT2A 2277/4885EPHX2 265/4885CASP3 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.